Nanoscope Therapeutics
Dallas, United States · Biotechnology, Health Care, Medical
Nanoscope Therapeutics is developing mutation-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases for which no treatment currently exists. Following positive end-of-study results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the company announced its plan to in
Key facts
- Headquarters
- Dallas, United States
- Employees
- 43
- Industries
- Biotechnology, Health Care, Medical
- Status
- Private
- Website
- nanostherapeutics.com
- Company page
Recent activity at Nanoscope Therapeutics
- : Nanoscope Therapeutics Appoints Troy Short as Senior Vice President
- : Nanoscope Therapeutics Appoints Paul Hallen as Chief Operating Officer
- : Nanoscope Therapeutics Appoints Ademola Daramola as Vice President, Quality and Compliance
- : Scilex Holding Company Regains Nasdaq Compliance and Focuses on Innovative Pain Management Solutions.
- : Scilex Holding Company extends maturity date of Senior Secured Promissory Note with Oramed Pharmaceuticals Inc.
- : Nanoscope Therapeutics Hires Ray Kaczmarek as Chief Technology and Manufacturing Officer
- : Scilex Holding Company Announces Collaboration with ACEA Therapeutics for ZTlido® Expansion in Far East Region
- : Nanoscope Therapeutics Inc. Appoints Khandan Baradaran as Senior Vice President of Regulatory and Quality
- : Scilex Holding Company Announces The Consummation Of The Previously Announced Purchase Of All Of The Scilex Common Shares, Preferred Shares And Warrants Owned By Sorrento Therapeutics, Inc.
- : Nanoscope Therapeutics Strengthens Clinical and Regulatory Expertise With Appointment of Samuel Barone, M.D., as Chief Medical Officer
Nanoscope Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Jul 2020 | Venture | $12.8M |
Leadership
- Troy Short, Senior Vice President
- Paul Hallen, Chief Operating Officer
- Ademola Daramola, Vice President
- Ray Kaczmarek, Chief Manufacturing Officer
- Khandan Baradaran, Vice President
- Samuel Barone, Chief Medical Officer
Verified email and direct lines for Nanoscope Therapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Nanoscope Therapeutics in the news
- Nanoscope Therapeutics Puts Rolling BLA for Retinitis Pigmentosa Gene Therapy MCO-010 in Front of FDA - CGTLive® (Jul 15, 2025)
- Nanoscope Therapeutics releases positive 3-year follow-up data from REMAIN study - Ophthalmology Times (Oct 24, 2025)
- Phase II Trial Demonstrates Vision Gains in Stargardt Disease With MCO-010 - Applied Clinical Trials (Aug 15, 2025)
- Nanoscope Nabs RMAT Designation for Retinitis Pigmentosa Gene Therapy MCO-010 - CGTLive® (Sep 04, 2025)
- Nanoscope Therapeutics releases positive long-term safety results from EXTEND study - Ophthalmology Times (Nov 05, 2025)
- Nanoscope Therapeutics to Participate in Eyecelerator 2026 and the American Academy of Ophthalmology 2026 Annual Meeting - PR Newswire (Oct 06, 2026)
- Nanoscope Therapeutics Announces Five New Clinical and Scientific Advisory Board Appointments - BioSpace (Feb 01, 2022)
- Nanoscope Therapeutics Announces First Patient Dosed in Phase 2b clinical trial of Optogenetic Gene Monotherapy to Restore Vision in Patients with Retinitis Pigmentosa - PR Newswire (Jul 19, 2021)
Companies similar to Nanoscope Therapeutics
- Grey Wolf Therapeutics · Biotechnology, Health Care, Medical, Therapeutics
- Specialised Therapeutics · Biotechnology, Health Care, Medical, Therapeutics
- NeuroKaire · Biotechnology, Health Care, Medical, Therapeutics
- Omnio · Biotechnology, Health Care, Medical, Therapeutics
- Aptose Biosciences · Biotechnology, Health Care, Medical, Therapeutics
About Nanoscope Therapeutics: questions and answers
What does Nanoscope Therapeutics do?
Nanoscope Therapeutics is developing mutation-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases for which no treatment currently exists. Following positive end-of-study results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the company announced its plan to in
Where is Nanoscope Therapeutics headquartered?
Nanoscope Therapeutics is headquartered in Dallas, United States.
How many employees does Nanoscope Therapeutics have?
Nanoscope Therapeutics has about 43 employees.
Has Nanoscope Therapeutics raised funding?
Yes. Fundz has recorded 1 funding event for Nanoscope Therapeutics. The most recent, $12.8M, was in Jul 2020.
Who leads Nanoscope Therapeutics?
Troy Short is a Senior Vice President at Nanoscope Therapeutics.
What is the latest news on Nanoscope Therapeutics?
On Oct 14, 2026, Nanoscope Therapeutics Appoints Troy Short as Senior Vice President
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy